| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine
|
Voorman, Arend
|
|
|
41 |
S1 |
p. A85-A92
|
artikel
|
| 2 |
Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020
|
Darwar, Roopa
|
|
|
41 |
S1 |
p. A25-A34
|
artikel
|
| 3 |
Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019–2021
|
Snider, Cynthia J.
|
|
|
41 |
S1 |
p. A58-A69
|
artikel
|
| 4 |
Editorial Board/Aims and Scope
|
|
|
|
41 |
S1 |
p. IFC
|
artikel
|
| 5 |
Editorial from guest editors for Vaccine supplement: Vaccine-derived poliovirus type 2 outbreaks after the cessation of use of oral poliovirus vaccine type 2-2016–2021
|
Wonodi, Chizoba
|
|
|
41 |
S1 |
p. A1
|
artikel
|
| 6 |
Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience
|
Macklin, Grace R.
|
|
|
41 |
S1 |
p. A122-A127
|
artikel
|
| 7 |
Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020
|
Macklin, Grace R
|
|
|
41 |
S1 |
p. A19-A24
|
artikel
|
| 8 |
Exploring public perceptions of vaccine-derived poliovirus and a novel oral polio vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria
|
Lorenzetti, Lara
|
|
|
41 |
S1 |
p. A128-A135
|
artikel
|
| 9 |
Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019–2020
|
Morais, Alda
|
|
|
41 |
S1 |
p. A48-A57
|
artikel
|
| 10 |
Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal
|
Harutyunyan, Vachagan
|
|
|
41 |
S1 |
p. A70-A78
|
artikel
|
| 11 |
Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic
|
Molodecky, Natalia A
|
|
|
41 |
S1 |
p. A93-A104
|
artikel
|
| 12 |
Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned
|
Afsar, Ahmet
|
|
|
41 |
S1 |
p. A79-A84
|
artikel
|
| 13 |
Outbreak response strategies with type 2-containing oral poliovirus vaccines
|
Kalkowska, Dominika A.
|
|
|
41 |
S1 |
p. A142-A152
|
artikel
|
| 14 |
Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies
|
Voorman, Arend
|
|
|
41 |
S1 |
p. A105-A112
|
artikel
|
| 15 |
Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks
|
Estivariz, Concepcion F.
|
|
|
41 |
S1 |
p. A113-A121
|
artikel
|
| 16 |
Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response
|
Kalkowska, Dominika A.
|
|
|
41 |
S1 |
p. A136-A141
|
artikel
|
| 17 |
The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities
|
Burkholder, Brent
|
|
|
41 |
S1 |
p. A2-A11
|
artikel
|
| 18 |
The impact of disruptions caused by the COVID-19 pandemic on global polio eradication
|
Kalkowska, Dominika A.
|
|
|
41 |
S1 |
p. A12-A18
|
artikel
|
| 19 |
Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021
|
Alleman, Mary M.
|
|
|
41 |
S1 |
p. A35-A47
|
artikel
|
Tijdschrift beschrijving